Monlunabant
Study of INV-202 in Patients With Obesity and Metabolic Syndrome
Inversago Pharma · Phase 2 · Completed · Enrollment 243
| Arm | Population | Dose | Weeks | Estimand | Weight change |
|---|---|---|---|---|---|
| Low dose | Obesity or overweight | n/r | n/r | n/r | n/r |
| High dose | Obesity or overweight | n/r | n/r | n/r | n/r |
| Placebo | Obesity or overweight | n/r | n/r | n/r | n/r |
| Middle Dose | Obesity or overweight | n/r | n/r | n/r | n/r |